Centauri Therapeutics
Alderley Park
About Centauri Therapeutics
Centauri is developing novel immunotherapeutics with a dual mechanism of action comprising (1) a moiety directly targeting cell surface antigens and (2) a glycan effector domain which triggers a potent pre-existing polyclonal immune response. This immune response triggers cell death through engagement with the target, enhanced complement fixation, antibody dependent cellular cytotoxicity, and phagocytosis by myeloid cells due to polyclonal antibody decoration of the target cell. Centauri has generated excellent pre-clinical in vitro data demonstrating the potent enhancement of complement fixation and opsonophagocytosis of anti-bacterial and oncology therapeutics as well as in vivo PoC data in multiple models of infection.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $55.4M
- Funding stage: Early Stage Venture
- Last round: Series A (Feb 2026)
- Website: centauritherapeutics.com
- Phone: +44 (0) 1304 728610
Industries & Categories
Biotechnology, Genetics, Health Care, Medical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/centauri-therapeutics-107344 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.